Targeting the alternative NF-κB pathway in pancreatic cancer: A new direction for therapy?

Expert Review of Anticancer Therapy

Volumn 13, Issue 5, 2013, Pages 501-504

  Storz, Peter ^a  

^a MAYO CLINIC   (United States)

Author keywords

alternative; MAP3K14; NF B; NIK; noncanonical; pancreatic cancer; therapy; TRAF2

Indexed keywords

2,7 NAPHTHYDRINE 1,3,6,8 TETRONE; 4H ISOQUINOLINE 1,3 DIONE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ACETYLSALICYLIC ACID; BORTEZOMIB; CARFILZOMIB; CELL PROTEIN; CHS 8282; CURCUMIN; FLAVONOID; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN 90; I KAPPA B BETA; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IXAZOMIB CITRATE; MLN 120B; NIK PROTEIN; NIK PROTEIN INHIBITOR; OPROZOMIB; PROTEIN INHIBITOR; PYRAZOLO[4,3 C]ISOQUINOLINE; PYRAZOLOISOQUINOLINE DERIVATIVE; SALAZOSULFAPYRIDINE; TAB PROTEIN; TNAP PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BAFF GENE; CANCER COMBINATION CHEMOTHERAPY; CCL19 GENE; CCL21 GENE; CXCL12 GENE; CXCL13 GENE; DRUG TARGETING; GENE; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED DIAGNOSIS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84876824209     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.28     Document Type: Review

References (27)

1. Sun SC. The noncanonical NF-κB pathway. Immunol. Rev. 246(1), 125-140 (2012).
2. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288(5467), 874-877 (2000).
3. Xiao G, Harhaj EW, Sun SC. NF-κBinducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7(2), 401-409 (2001).
4. Wharry CE, Haines KM, Carroll RG, May MJ. Constitutive non-canonical NFκB signaling in pancreatic cancer cells. Cancer Biol. Ther. 8(16), 1567-1576 (2009).
5. Chandler NM, Canete JJ, Callery MP. Increased expression of NF-κB subunits in human pancreatic cancer cells. J. Surg. Res. 118(1), 9-14 (2004).
6. Nishina T, Yamaguchi N, Gohda J, Semba K, Inoue J. NIK is involved in constitutive activation of the alternative NF-κB pathway and proliferation of pancreatic cancer cells. Biochem. Biophys. Res. Commun. 388(1), 96-101 (2009).
7. Döppler H, Liou GY, Storz P. Downregulation of TRAF2 mediates NIKinduced pancreatic cancer cell proliferation and tumorigenicity. PLoS ONE 8(1), e53676 (2013).
8. Schneider G, Saur D, Siveke JT, Fritsch R, Greten FR, Schmid RM. IKKα controls p52/RelB at the skp2 gene promoter to regulate G1-to S-phase progression. EMBO J. 25(16), 3801-3812 (2006).
9. Annunziata CM, Davis RE, Demchenko Y et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2), 115-130 (2007).
10. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12(9), 1543-1568 (2007).
11. Mortier J, Masereel B, Remouchamps C, Ganeff C, Piette J, Frederick R. NF-κB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. Bioorg. Med. Chem. Lett. 20(15), 4515-4520 (2010).
12. de Leon-Boenig G, Bowman KK, Feng JA et al. The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site. Structure 20(10), 1704-1714 (2012).
13. Liu J, Sudom A, Min X et al. Structure of the nuclear factor κB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation. J. Biol. Chem. 287(33), 27326-27334 (2012).
14. Zhang T, Hamza A, Cao X et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7(1), 162-170 (2008).
15. Qing G, Yan P, Qu Z, Liu H, Xiao G. Hsp90 regulates processing of NF-κ B2 p100 involving protection of NF-κ B-inducing kinase (NIK) from autophagy-mediated degradation. Cell Res. 17(6), 520-530 (2007).
16. Hu WH, Mo XM, Walters WM, Brambilla R, Bethea Jr. TNAP, a novel repressor of NF-κB-inducing kinase, suppresses NF-κB activation. J. Biol. Chem. 279(34), 35975-35983 (2004).
17. Nawrocki ST, Carew JS, Pino MS et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66(7), 3773-3781 (2006).
18. Dai Y, Liu M, Tang W et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin. Cancer Res. 14(23), 7701-7710 (2008).
19. Luqman S, Pezzuto JM. NFκB: a promising target for natural products in cancer chemoprevention. Phytother. Res. 24(7), 949-963 (2010).
20. Fendrich V, Chen NM, Neef M et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59(5), 630-637 (2010).
21. Xu Y, Fang F, St Clair DK, Sompol P, Josson S, St Clair WH. SN52, a novel nuclear factor-κB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol. Cancer Ther. 7(8), 2367-2376 (2008).
22. Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 25(51), 6887-6899 (2006).
23. Thu YM, Richmond A. NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev. 21(4), 213-226 (2010).
24. Baud V, Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8(1), 33-40 (2009).
25. Flohr S, Naumann T. Pyrazoloisoquinoline derivates for inhibiting NF-κB-inducing kinase. US-6841556-B2 (2005).
26. Majid TN, Hopkins C, Pedgrift BL, Collar N, Wirtz-Brugger F, Merrill J. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders. US-7132428-B2 (2006).
27. Chen G, Cushing TD, Faulder P et al. Alkynyl alcohols as kinase inhibitors. US2011/0086834-A1 (2009).